Leave a Comment:
I sent you information to your email address. Let me know if you have any questions.
I just got diagnosed with multiple myeloma and was wondering about using cannabis oils while doing chemotherapy. I am leaning on using at least cbd oils but also considering thc/cbd oils before bed. Your thoughts? Have you used cannabis since your diagnosis?Reply
I am sorry to learn of your MM diagnosis. While research of CBD and cannabinoids and multiple myeloma is minimal, there are a number of studies that cite cannabinoids as
an effective therapy to reduce pain
an effective therapy to reduce anxiety
an effective therapy to heal bone and increase bone mineral density
an integrative therapy meaning cannabinoids enhance the efficacy of Bortezomib (Velcade)
And possibly an effective therapy against multiple myeloma itself though the research is limited.
Several responses to your questions.
No I have not used cannabis since my diagnosis. I live in Ohio. While cannabis has been approved for medical uses, there still is limited availability and little understanding of this complementary therapy by medical doctors.
As for sleep therapy, yes, I have read several accounts where cancer patients take CBD before bed and enjoy a restful night’s sleep.
I will link the studies below that cite what I am saying above.
Let me know if you have any other questions. Good luck,
Cannabinoids in the management of difficult to treat pain
“This article reviews recent research on cannabinoid analgesia via the endocannabinoid system and non-receptor mechanisms, as well as randomized clinical trials employing cannabinoids in pain treatment.
Tetrahydrocannabinol (THC, Marinol®) and nabilone (Cesamet®) are currently approved in the United States and other countries, but not for pain indications. Other synthetic cannabinoids, such as ajulemic acid, are in development. Crude herbal cannabis remains illegal in most jurisdictions but is also under investigation.
Sativex®, a cannabis derived oromucosal spray containing equal proportions of THC (partial CB1 receptor agonist ) and cannabidiol (CBD, a non-euphoriant, anti-inflammatory analgesic with CB1receptor antagonist and endocannabinoid modulating effects) was approved in Canada in 2005 for treatment of central neuropathic pain in multiple sclerosis, and in 2007 for intractable cancer pain.
Numerous randomized clinical trials have demonstrated safety and efficacy for Sativex in central and peripheral neuropathic pain, rheumatoid arthritis and cancer pain. An Investigational New Drug application to conduct advanced clinical trials for cancer pain was approved by the US FDA in January 2006.
Cannabinoid analgesics have generally been well tolerated in clinical trials with acceptable adverse event profiles. Their adjunctive addition to the pharmacological armamentarium for treatment of pain shows great promise…”
Cannabidiol as a Potential Treatment for Anxiety Disorders
“Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders.
The purpose of the current review is to determine CBD’s potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, human experimental, clinical, and epidemiological studies.
We found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive–compulsive disorder, and post-traumatic stress disorder when administered acutely; however, few studies have investigated chronic CBD dosing.
Likewise, evidence from human studies supports an anxiolytic role of CBD, but is currently limited to acute dosing, also with few studies in clinical populations. Overall, current evidence indicates CBD has considerable potential as a treatment for multiple anxiety disorders, with need for further study of chronic and therapeutic effects in relevant clinical populations…”
No bones about it: Cannabis may be used to treat fractures
“A new study published in the Journal of Bone and Mineral Research by Tel Aviv University and Hebrew University researchers explores another promising new medical application for marijuana.
According to the research, the administration of the non-psychotropic component cannabinoid cannabidiol (CBD) significantly helps heal bone fractures. The study, conducted on rats with mid-femoral fractures, found that CBD — even when isolated from tetrahydrocannabinol (THC), the major psychoactive component of cannabis — markedly enhanced the healing process of the femora after just eight weeks.
The research was led jointly by Dr. Yankel Gabet of the Bone Research Laboratory at the Department of Anatomy and Anthropology at TAU’s Sackler Faculty of Medicine and the late Prof. Itai Bab of Hebrew University’s Bone Laboratory…”
The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2
“Multiple myeloma (MM) is a plasma cell (PC) malignancy characterised by the accumulation of a monoclonal PC population in the bone marrow (BM).
Cannabidiol (CBD) is a non-psychoactive cannabinoid with antitumoural activities, and the transient receptor potential vanilloid type-2 (TRPV2) channel has been reported as a potential CBD receptor. TRPV2 activation by CBD decreases proliferation and increases susceptibility to drug-induced cell death in human cancer cells…
In this study, we identified the presence of heterogeneous CD138+TRPV2+ and CD138+TRPV2- PC populations in MM patients, whereas only the CD138+ TRPV2- population was present in RPMI8226 and U266 MM cell lines.
Because bortezomib (BORT) is commonly used in MM treatment, we investigated the effects of CBD and BORT in CD138+TRPV2- MM cells and in MM cell lines transfected with TRPV2 (CD138+TRPV2+).
These results showed that CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-κB pathways with major effects in TRPV2+ cells. These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM…”Reply
I was diagnosed with Multiple Myeloma approximately 6 months ago. Had bone marrow transplant and have gone from 70% to 6% myeloma. What medical cannabis would you recommendReply
I am sorry to learn of your MM diagnosis but glad to read of your very good partial remission (VGPR). Because CBD oil is a state by state issue in the U.S., there is no single “best” brand or formula. The research that I’ve read cites the percentage of cannabinoids as being the most important in the CBD oil. The brands of CBD oil available on the internet, for example, by law, are made from industrial hemp and result in a very low percentage of cannabinoids.
I will link a blog post below that cites the names of CBD strains that have high percentage of cannabinoids.
I should also put in a plug for the ability of anti-MM nutrition, supplementation and specific lifestyle therapies shown to also fight MM-
Hi David, I was diagnosed last October with Multiple Myloma and went rapidly into hospital in Glasgow, Scotland, for 5 doses of Radiotherapy. I then became an outpatient and began Chemotherapy. After 4 courses I was very surprised to be showing almost nil Para- Protiens, and as I was very high, 60odd some months earlier, everyone was surprised with my progress. My Doctor described it as undetectable just before I we t inside again for a Stem Cell Transplant which I’ve since completed, so I’m just waiting on an update from my Consultant.Reply
I’d like some advice, if possible, regarding use of THC, as I had been using it just before the SCT, and some words on diet and excersize, if possible.